Literature DB >> 20563545

[Hypertension and heart].

M Hennersdorf1, C M Schannwell, W Motz.   

Abstract

Arterial hypertension often leads to diseases of kidneys, vessels and brain. Besides these end organ damages the changes of the heart are of important role. Substantial consequences of hypertension are microangiopathy, interstitial fibrosis and left ventricular hypertrophy. Hence, as an early stage diastolic dysfunction results. Due to longer persistent hypertension also systolic dysfunction develops. Clinically, patients suffer from angina pectoris, dyspnoea and cardiac arrhythmias (i.e. atrial arrhythmia, atrial fibrillation). The left ventricular hypertrophy also is associated with an increased risk of malignant ventricular arrhythmias. The risk of sudden cardiac death is raised as well, in particular in patients with dilated heart and reduced left ventricular ejection fraction. Well controlled antihypertensive therapy could lead to a regression of left ventricular hypertrophy. Hence, disorders and prognosis of the patients could be improved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20563545     DOI: 10.1007/s00108-009-2556-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  50 in total

Review 1.  Electrophysiological remodeling in hypertrophy and heart failure.

Authors:  G F Tomaselli; E Marbán
Journal:  Cardiovasc Res       Date:  1999-05       Impact factor: 10.787

2.  Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.

Authors:  Paolo Verdecchia; Fabio Angeli; Roberto Gattobigio; Mariagrazia Sardone; Sergio Pede; Gian Paolo Reboldi
Journal:  Am J Hypertens       Date:  2006-05       Impact factor: 2.689

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

4.  Prognostic value of arrhythmogenic markers in systemic hypertension.

Authors:  M Galinier; S Balanescu; J Fourcade; M Dorobantu; J P Albenque; P Massabuau; J P Doazan; J M Fauvel; J P Bounhoure
Journal:  Eur Heart J       Date:  1997-09       Impact factor: 29.983

5.  Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease.

Authors:  B Schwartzkopff; M Brehm; M Mundhenke; B E Strauer
Journal:  Hypertension       Date:  2000-08       Impact factor: 10.190

6.  Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Authors:  Paolo Verdecchia; Peter Sleight; Giuseppe Mancia; Robert Fagard; Bruno Trimarco; Roland E Schmieder; Jae-Hyung Kim; Garry Jennings; Petr Jansky; Jyh-Hong Chen; Lisheng Liu; Peggy Gao; Jeffrey Probstfield; Koon Teo; Salim Yusuf
Journal:  Circulation       Date:  2009-09-21       Impact factor: 29.690

Review 7.  Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.

Authors:  J Stamler; R Stamler; J D Neaton
Journal:  Arch Intern Med       Date:  1993-03-08

8.  Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study).

Authors:  Mintu P Turakhia; Nelson B Schiller; Mary A Whooley
Journal:  Am J Cardiol       Date:  2008-08-27       Impact factor: 2.778

9.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

10.  Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension.

Authors:  E A Karpanou; G P Vyssoulis; A Psichogios; C Malakou; E A Kyrozi; D V Cokkinos; P K Toutouzas
Journal:  Am Heart J       Date:  1998-11       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.